Insider Selling: Genomic Health, Inc. (GHDX) CFO Sells $1,005,450.00 in Stock

Genomic Health, Inc. (NASDAQ:GHDX) CFO G Bradley Cole sold 15,000 shares of the stock in a transaction dated Tuesday, January 8th. The stock was sold at an average price of $67.03, for a total transaction of $1,005,450.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, December 11th, G Bradley Cole sold 15,000 shares of Genomic Health stock. The stock was sold at an average price of $71.95, for a total transaction of $1,079,250.00.
  • On Tuesday, November 13th, G Bradley Cole sold 8,576 shares of Genomic Health stock. The stock was sold at an average price of $79.18, for a total transaction of $679,047.68.

Shares of NASDAQ GHDX opened at $70.12 on Friday. The company has a market capitalization of $2.46 billion, a P/E ratio of 7,012.00 and a beta of 0.73. Genomic Health, Inc. has a 1 year low of $30.04 and a 1 year high of $92.18.



Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $0.28. The business had revenue of $101.30 million during the quarter, compared to analyst estimates of $94.27 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.06) EPS. On average, equities analysts expect that Genomic Health, Inc. will post 1.06 earnings per share for the current year.

A number of research analysts have recently commented on the stock. BidaskClub raised shares of Genomic Health from a “buy” rating to a “strong-buy” rating in a report on Wednesday. Needham & Company LLC assumed coverage on shares of Genomic Health in a report on Wednesday, January 2nd. They issued a “strong-buy” rating and a $86.00 target price for the company. CIBC began coverage on shares of Genomic Health in a report on Wednesday, December 19th. They issued a “market perform” rating for the company. Oppenheimer began coverage on shares of Genomic Health in a report on Wednesday, December 19th. They issued a “market perform” rating for the company. Finally, ValuEngine lowered shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a report on Tuesday, December 11th. Nine research analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $58.50.

Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new stake in Genomic Health during the 2nd quarter valued at approximately $162,000. Pacer Advisors Inc. acquired a new stake in Genomic Health during the 3rd quarter valued at approximately $171,000. Trexquant Investment LP acquired a new stake in Genomic Health during the 3rd quarter valued at approximately $202,000. D.A. Davidson & CO. acquired a new stake in Genomic Health during the 3rd quarter valued at approximately $234,000. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in Genomic Health during the 2nd quarter valued at approximately $315,000. Institutional investors and hedge funds own 89.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2019/01/12/insider-selling-genomic-health-inc-ghdx-cfo-sells-1005450-00-in-stock.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Recommended Story: What impact do institutional investors have on markets?

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply